Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products for the treatment and prevention of serious infectious diseases. It develops VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; VIR-1111 for the prevention of human immunodeficiency virus, and VIR-2020 for the prevention of tuberculosis. The company has grant agreement with Bill & Melinda Gates Foundation and National Institutes of Health; option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; collaboration and license agreement Alnylam Pharmaceuticals, Inc.; collaboration, license and option agreement Visterra, Inc.; and license agreement with The Rockefeller University and MedImmune, Inc. It operates in the United States, Oregon, Massachusetts, and Switzerland. The company was founded in 2016 and is headquartered in San Francisco, California.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone415-906-4324
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees206
Next Earnings DateN/A
OptionableNot Optionable
Vir Biotechnology (NYSE:VIR) Frequently Asked Questions
What is Vir Biotechnology's stock symbol?
Vir Biotechnology trades on the New York Stock Exchange (NYSE) under the ticker symbol "VIR."
What price target have analysts set for VIR?
4 Wall Street analysts have issued 12-month price targets for Vir Biotechnology's stock. Their forecasts range from $25.00 to $37.00. On average, they expect Vir Biotechnology's share price to reach $29.00 in the next twelve months. This suggests a possible upside of 118.5% from the stock's current price. View Analyst Price Targets for Vir Biotechnology.
What is the consensus analysts' recommendation for Vir Biotechnology?
4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vir Biotechnology in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vir Biotechnology.
Has Vir Biotechnology been receiving favorable news coverage?
News coverage about VIR stock has been trending very negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Vir Biotechnology earned a media sentiment score of -3.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Vir Biotechnology.
Who are some of Vir Biotechnology's key competitors?
Some companies that are related to Vir Biotechnology include Cronos Group (CRON), MorphoSys (MOR), BTG (BTG), MorphoSys (MOR), Asterias Biotherapeutics (AST), Abcam (ABC), Genus (GNS), Clinuvel Pharmaceuticals (CUV), Polynovo (PNV), Concordia International (CXR), Immutep (IMM), Mesoblast (MSB), Kodiak Sciences (KOD), Paradigm Biopharmaceuticals (PAR) and Starpharma (SPL).
What other stocks do shareholders of Vir Biotechnology own?
Who are Vir Biotechnology's key executives?
Vir Biotechnology's management team includes the folowing people:
- Dr. George A. Scangos, Pres, CEO & Director (Age 71)
- Dr. Jay Parrish, Chief Bus. Officer & Co-Founder (Age 44)
- Dr. Klaus Frueh, Co-Founder & Director (Age 59)
- Mr. Robert Taylor Nelsen M.B.A., Co-Founder & Director (Age 57)
- Dr. Lawrence Corey, Co-Founder & Scientific Advisor
When did Vir Biotechnology IPO?
(VIR) raised $149 million in an initial public offering (IPO) on Friday, October 11th 2019. The company issued 7,100,000 shares at a price of $20.00-$22.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Barclays acted as the underwriters for the IPO.
When does the company's quiet period expire?
Vir Biotechnology's quiet period expires on Wednesday, November 20th. Vir Biotechnology had issued 7,142,858 shares in its IPO on October 11th. The total size of the offering was $142,857,160 based on an initial share price of $20.00. During the company's quiet period, underwriters and any insiders that worked on the IPO are prevented from issuing any research reports or earnings estimates for the company because of regulations issued by the Securities and Exchange Commission. Following the end of the company's quiet period, it's expected that the brokerages that served as underwriters on the stock will initiate research coverage on the company.
How do I buy shares of Vir Biotechnology?
Shares of VIR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Vir Biotechnology's stock price today?
One share of VIR stock can currently be purchased for approximately $13.27.
How big of a company is Vir Biotechnology?
What is Vir Biotechnology's official website?
How can I contact Vir Biotechnology?
The company can be reached via phone at 415-906-4324.
MarketBeat Community Rating for Vir Biotechnology (NYSE VIR)
MarketBeat's community ratings are surveys of what our community members think about Vir Biotechnology and other stocks. Vote "Outperform" if you believe VIR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VIR will underperform the S&P 500 over the long term. You may vote once every thirty days.
